On June 19, 2026, SOPHiA GENETICS, a prominent company specializing in Ai-powered precision medicine, revealed the completion of its underwritten public offering that resulted in total gross earnings of $57.5 million, before deducting any expenses. The offering was successful and reaffirmed the company's position as a leader in the field.